We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
At the 2013 Drug Delivery Partnership conference, West’s Bart Burgess partnered with Peter Krulevitch, Ph.D., Engineering Director, Packaging, Devices & Delivery, Janssen Pharmaceutical Companies of Johnson & Johnson to discuss West and Janssen’s unique partnership. Together, West and Janssen are developing the SelfDoseTM injector platform technology.*
The partnership began as an effort to meet patient needs with a simple, friendly self-administration device that would deliver Janssen biologic drug products. The product would need a reliable design that would be compatible with Janssen’s fill/finish infrastructure and easy to use for a range of patients.
Janssen has partnered with West to develop and manufacture the new SelfDose Injector Technology , an easy-to-use system designed for subcutaneous injection.
*For investigational use only for our pharmaceutical and biotechnology development partners; SelfDose [TM] has not been cleared or approved by the FDA as a standalone product.
SelfDose™ is a trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. West seeks partners for its SelfDose™ injector technology platform. This platform is intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.
We are excited to share that Bernard Birkett, Senior Vice President & Chief Financial Officer, has been recognized as a 2020 CFO of the Year Award Winner by the <em>Philadelphia Business Journal</em>.
Particles in parenteral drug products continue to be an important concern. At the April-2017 AAPS Workshop <strong>Challenges and Patient Impact of Particles in Biologics</strong>, Fran DeGrazio, VP of Scientific Affairs and Technical Services, spoke on the topic: <em>Unique Considerations for Testing and Understanding Particle Loads for Primary Packaging Components.</em> <br />
Have you thought about the complexities of a patient’s journey through treatment? Navigating from leukemia diagnosis to treatment can be a difficult one. Informing family members, managing loved ones’ reactions, weighing the many different treatment options and facing the reality of multiple hospital visits can be overwhelming.
<p><span>Anti-VEGF therapeutics for the treatment of ophthalmic conditions such as neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME) have significantly improved patient prognoses, in some cases preventing or reversing progression to blindness. Routine injections into the eye of recombinant protein drugs such as bevacizumab, ranibizumab or aflibercept have proven to be efficacious in neutralizing the binding of over-expressed vascular endothelial growth factor (VEGF) proteins to their corresponding cellular receptors, thus interrupting the angiogenesis signaling pathway which otherwise leads to the disease states. In short, anti-VEGF injections are preventing or restoring vision loss for millions of people world-wide.</span></p>
Diane Paskiet, Director, Scientific Affairs, will present at two sessions during the <strong>2012 PDA Annual Meeting. The meeting will be held from April 16-18, 2012 at the JW Marriott Desert Ridge Resort in Phoenix, Arizona.</strong>
English
Chinese
